Xuening Yang

7PUBLICATIONS
31CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 16, 2026
Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial.

|Jan 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.

Jia-Tao Zhang, Si-Yang Liu, Xuan Gao

|Dec 25, 2023
Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study.

Jun-Tao Lin, Xiang-Meng Li, Wen-Zhao Zhong

|Dec 06, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.

Si-Yang Liu, Song Dong, Xue-Ning Yang

|Nov 25, 2022
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial.

Cunte Chen, Siyang Maggie Liu, Yedan Chen

|Dec 17, 2020
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

Wen-Zhao Zhong, Qun Wang, Wei-Min Mao

Pageof 2

Frequent Collaborators

6 joint publications

Yi-Long Wu

4 joint publications

Wen-Zhao Zhong

3 joint publications

Qing Zhou

3 joint publications

Si-Yang Liu